S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
NASDAQ:AMRN

Amarin (AMRN) Stock Forecast, Price & News

$1.28
+0.07 (+5.79%)
(As of 06/2/2023 ET)
Compare
Today's Range
$1.21
$1.28
50-Day Range
$1.16
$1.54
52-Week Range
$1.04
$2.23
Volume
2.35 million shs
Average Volume
2.06 million shs
Market Capitalization
$516.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50

Amarin MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
95.3% Upside
$2.50 Price Target
Short Interest
Healthy
5.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.02mentions of Amarin in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.15) to ($0.22) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars

Medical Sector

722nd out of 983 stocks

Pharmaceutical Preparations Industry

360th out of 486 stocks


AMRN stock logo

About Amarin (NASDAQ:AMRN) Stock

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Receive AMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

AMRN Stock News Headlines

Save $200 on MarketBeat All Access
MarketBeat All Access is the premier all-in-one stock research solution that helps you identify the best stocks, monitor your portfolio, and keep track of the market. You get our top stock picks, best-in-class research tools, real-time alerts, proprietary research reports and much more. Claim your $200 account credit and free 30-day trial subscription today.
StockNews.com Initiates Coverage on Amarin (NASDAQ:AMRN)
15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Short Interest in Amarin Co. plc (NASDAQ:AMRN) Grows By 17.6%
Analysts Set Amarin Co. plc (NASDAQ:AMRN) Price Target at $2.38
See More Headlines

AMRN Price History

AMRN Company Calendar

Last Earnings
11/03/2021
Today
6/03/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMRN
Fax
N/A
Employees
560
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$2.50
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+95.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-105,800,000.00
Pretax Margin
-24.95%

Debt

Sales & Book Value

Annual Sales
$369.19 million
Book Value
$1.45 per share

Miscellaneous

Free Float
400,195,000
Market Cap
$516.90 million
Optionable
Optionable
Beta
1.78

Social Links


Key Executives

  • Aaron D. Berg
    President & Chief Executive Officer
  • Derek Kalinowski
    SVP-Manufacturing Operations
  • Thomas Reilly
    Chief Financial Officer & SVP
  • Steven B. KetchumSteven B. Ketchum
    Chief Scientific Officer & Executive VP
  • Nabil A. Abadir
    Chief Medical Officer-Global Medical Affairs













AMRN Stock - Frequently Asked Questions

Should I buy or sell Amarin stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AMRN shares.
View AMRN analyst ratings
or view top-rated stocks.

What is Amarin's stock price forecast for 2023?

2 brokers have issued 12 month target prices for Amarin's stock. Their AMRN share price forecasts range from $2.00 to $3.00. On average, they anticipate the company's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 95.3% from the stock's current price.
View analysts price targets for AMRN
or view top-rated stocks among Wall Street analysts.

How have AMRN shares performed in 2023?

Amarin's stock was trading at $1.21 at the start of the year. Since then, AMRN shares have increased by 5.8% and is now trading at $1.28.
View the best growth stocks for 2023 here
.

Are investors shorting Amarin?

Amarin saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 20,980,000 shares, a decrease of 12.8% from the April 30th total of 24,070,000 shares. Based on an average trading volume of 3,200,000 shares, the short-interest ratio is presently 6.6 days.
View Amarin's Short Interest
.

When is Amarin's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our AMRN earnings forecast
.

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) posted its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.01. The biopharmaceutical company earned $142 million during the quarter, compared to analysts' expectations of $161.29 million. Amarin had a negative net margin of 25.16% and a negative trailing twelve-month return on equity of 15.45%. The company's revenue was down 8.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.02) EPS.

What ETFs hold Amarin's stock?
What is John Thero's approval rating as Amarin's CEO?

43 employees have rated Amarin Chief Executive Officer John Thero on Glassdoor.com. John Thero has an approval rating of 93% among the company's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend.

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

Who are Amarin's major shareholders?

Amarin's stock is owned by a number of institutional and retail investors. Top institutional investors include Two Sigma Investments LP (1.38%), DG Capital Management LLC (1.36%), Sarissa Capital Management LP (1.22%), 13D Management LLC (1.03%), Acadian Asset Management LLC (0.82%) and Two Sigma Advisers LP (0.71%). Insiders that own company stock include David M Stack, John F Thero, Joseph S Zakrzewski, Michael Wayne Kalb, Olsen Per Wold and Steven B Ketchum.
View institutional ownership trends
.

How do I buy shares of Amarin?

Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $1.28.

How much money does Amarin make?

Amarin (NASDAQ:AMRN) has a market capitalization of $516.90 million and generates $369.19 million in revenue each year. The biopharmaceutical company earns $-105,800,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis.

How many employees does Amarin have?

The company employs 560 workers across the globe.

Does Amarin have any subsidiaries?
The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.
Read More
How can I contact Amarin?

Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The official website for the company is www.amarincorp.com. The biopharmaceutical company can be reached via phone at (531) 669-9020 or via email at investor.relations@amarincorp.com.

This page (NASDAQ:AMRN) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -